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Background: The neutrophil-lymphocyte ratio (NLR) has been proposed as an indicator of systemic inflammatory
response and may predict the clinical outcome in some cancers, such as head and neck cancer and gastric cancer.
However, the value of this ratio is variable in different cancers. Studies of the relationship between NLR and both
survival and response to chemoradiation have been limited with respect to locally advanced rectal cancer.
Methods and materials: From 2006 to 2011, 199 consecutive locally advanced rectal cancer patients who were
treated with neoadjuvant chemoradiation in the Shanghai Cancer Center were enrolled and analysed
retrospectively. Tumor response was evaluated by pathological findings. The baseline total white blood cell count
(WBC) and the neutrophil, lymphocyte, platelet counts were recorded. The neutrophil-lymphocyte ratio (NLR) and
the relationship with clinical outcomes such as overall survival (OS) and disease-free survival (DFS) was analyzed.
Results: With ROC analysis, the baseline NLR value was found to significantly predict prognosis in terms of OS well
in locally advanced rectal cancer patients. A multivariate analysis identified that a cut-off value of NLR ≥ 2.8 could
be used as an independent factor to indicate decreased OS (HR, 2.123; 95% CI, 1.140-3.954; P = 0.018). NLR ≥ 2.8 was
also associated with worse DFS in univariate analysis (HR, 1.662; 95% CI, 1.037-2.664; P = 0.035), though it was not
significant in the multivariate analysis (HR, 1.363; 95% CI, 0.840-2.214; P = 0.210). There was no observed significant
correlation of mean value of NLR to the response to neoadjuvant chemoradiation. The mean NLR in the ypT0-2 N0
group was 2.68 ± 1.38, and it was 2.77 ± 1.38 in the ypT3-4/N+ group, with no statistical significance (P = 0.703). The
mean NLR in the TRG 0–1 group was 2.68 ± 1.42, and it was 2.82 ± 1.33 in the TRG 2–3 group with no statistical
significance (P = 0.873).
Conclusions: An elevated baseline NLR is a valuable and easily available prognostic factor for OS in addition to
tumor response after neoadjuvant therapy. Baseline NLR could be a useful candidate factor for stratifying patients
and making treatment decisions in locally advanced rectal cancer.
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Neoadjuvant chemoradiation therapy (NACRT) has been
established as a standard treatment for locally advanced
rectal cancer (LARC). Patients who achieve complete
pathological response after chemoradiation show a* Correspondence: zhenzhang6@hotmail.com
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and conventional clinicopathological prognostic variables
remain the primary assessment, researchers have attem-
pted to quantify tumor response to neoadjuvant chemora-
diation and predict prognosis using other factors. Many
studies have focused on the prognostic significance
of genes, proteins and inflammatory factors, but no
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risk-stratified therapy in locally advanced rectal cancer.
Recently, the local and systemic inflammatory response
has been reported as an important determinant of disease
progression and survival in colorectal cancer [3]. The
Glasgow prognostic score, which is based on elevated
circulating concentrations of C-reactive protein and
hypoalbuminaemia, is independently associated with poor
survival [4]. Other inflammatory parameters such as inter-
leukins, TGFβ and VEGF have also been found to be asso-
ciated with outcome [5]. However, these parameters are
not routinely measured in daily clinical practice. The
systemic inflammatory response measured using the sur-
rogate neutrophil-lymphocyte ratio (NLR) has been pro-
posed as an inexpensive and widely available marker to
predict cancer patient survival [6]. Several studies have
demonstrated that elevated NLR was associated with in-
ferior survival in several common cancers, including colo-
rectal cancer [7-9], gastric cancer [10], renal cancer [11],
breast cancer [12] and pancreatic cancer [13]. The causes
of this inferior survival have not yet been identified, but an
elevated NLR is thought to correlate with the decline of
nutrition and immune function. More specifically in lo-
cally advanced rectal cancer (LARC) patients, some stud-
ies have demonstrated that an elevated lymphocyte count
is associated with increased downstaging following neoad-
juvant chemoradiation [14], while elevated NLR is asso-
ciated with short time to local recurrence (TTLR) and
worse overall survival (OS) and disease-free survival (DFS)
[15]. However, with regard to the response of neoadjuvant
chemoradiation and prognosis in locally advanced rectal
cancer patients, there are still relatively few studies also
with small number of patients have focused on this issue.
In addition, it’s very important to discriminate different
risk groups up front, because this may influence the treat-
ment modality choosing for these patients. If the patients’
baseline characteristics can be stratified into different risk
groups, we may avoid over-treatment for patients with
good prognosis while intensify treatment for patients with
poor prognosis.
Therefore, the aim of our study is to further clarify the
prognostic significance of the baseline NLR in locally ad-
vanced rectal cancer with neoadjuvant chemoradiation
and its relationship with radiation response.
Methods
Patients and evaluation
A consecutive cohort of 224 patients with locally ad-
vanced (cT3-4 and/or cN1-2) rectal cancer treated with
neoadjuvant chemoradiotherapy followed by surgery at
the Fudan University Shanghai Cancer Center between
January 2006 and December 2011 was identified from
the colorectal cancer database. All medical records were
retrospectively reviewed.Primary tumors were staged by MRI. All patients
underwent conventional radiation with concurrent 5-
fluorouracil-based chemotherapy. The mean radiation
dose was 50 Gy (range 45–55 Gy) with daily fraction of
1.8-2.0 Gy. Radiation treatments were performed accor-
ding to the institutional protocols. For the analysis in
this study, the exclusion criteria included patients who
did not have rectal adenocarcinoma, were diagnosed
with a non–skin cancer within 5 years of the diagnosis of
rectal cancer, did not complete neoadjuvant chemoradia-
tion, were found to have metastatic disease before or at
the time of surgery or had an interval from the completion
of radiation to surgery greater than 16 weeks.
In this data set, 208 patients met the criteria, and 199
patients had retrievable baseline blood sampling reports
within 7 days before the start of chemoradiation. The
blood routine examination was detected by fluorescence
flow cytometry in our center. The total white blood cell
count (WBC) and the neutrophil, lymphocyte and platelet
counts were recorded. The neutrophil-lymphocyte ratio
(NLR) was calculated by dividing the absolute neutrophil
count by the absolute lymphocyte count. The pre-
treatment carcinoembryonic antigen (CEA) levels were
categorised as normal (<5 ng/ml) or elevated (≥5 ng/ml).
Pathologic tumor staging of the surgical specimen was
performed in accordance with the 7th guidelines of the
American Joint Committee on Cancer [16]. Written in-
formed consent was obtained from the patient for the
publication of this report and any accompanying images
and this study was approved by the Institutional Review
Board of Fudan University Shanghai Cancer Center.
The primary endpoint of the study was overall survival
(OS) and disease-free survival (DFS). The secondary
endpoint was neoadjuvant chemoradiation response. OS
was defined as the time from the date of surgery to
death from any cause. DFS was defined as the time from
the date of surgery to the date of tumor relapse (local
recurrence and/or distant metastases) or death. We eva-
luated tumor response with both ypTNM staging and
TRG score. In the ypTNM staging system, good response
was defined as ypT0 to 2 without lymph node metastases,
and poor response was defined as ypT3 to 4 or with iden-
tified lymph node metastases. The four-point TRG system
graded on a scale of 0(complete response; no viable cancer
cells) to 3 (poor response; minimal or no regression, ex-
tensive residual cancer) [16]. Patients with TRG0-1 had
good response while TRG2-3 had poor response.
Statistical analysis
Receiver operating characteristic (ROC) analysis and rela-
tive area under the curve (AUC) statistics were used, and
the ratio closest to the point with the maximum sensitivity
and specificity was selected as the optimal cut-off value.
The NLR was correlated with the clinicopathological
Table 1 Patient characteristics
Variables N (%) Low NLR (%) High NLR(%) P-value
Gender
Female 50 (25.1) 35 (70.0) 15 (30.0)
Male 149 (74.9) 98 (65.8) 51 (34.2) 0.583
Age, years
<60 135 (67.2) 90 (66.7) 45 (33.3)
≥60 64 (31.8) 43 (67.2) 21 (32.8) 0.942
Tumor stage before CRT
II 26 (13.1) 23 (88.5) 3 (11.5)
III 173 (86.9) 110 (63.6) 63 (36.4) 0.012
Tumor location
Low 122 (61.3) 82 (67.2) 40 (32.8)
Middle-high 77 (38.7) 51 (66.2) 26 (33.8) 0.886
CEA, ng/ml
<5 110 (55.3) 77 (70.0) 33 (30.0)
≥5 89 (44.7) 56 (62.9) 33 (37.1) 0.292
RT dose, Gy
45-50 122 (61.3) 76 (62.3) 46 (37.7)
>50 77 (38.7) 57 (74.0) 20 (26.0) 0.087
Surgical procedure
APR 115 (57.8) 81 (70.4) 34 (29.6)
LAR 70 (35.2) 45 (64.3) 25 (35.7)
Hartmann 14 (7.0) 7 (50.0) 7 (50.0) 0.246*
ypTNM staging
ypT0-2 N0 88 (44.2) 62 (70.5) 26 (29.5)
ypT3-4 or N+ 111 (55.8) 71 (64.0) 40 (36.0) 0.334
TRG score
0-1 117 (58.8) 82 (70.1) 35 (29.9)
2-3 82 (41.2) 51 (62.2) 31 (37.8) 0.245
Adjuvant chemotherapy
Yes 184 (92.5) 121 (65.8) 63 (34.2)
No 15 (7.5) 12 (80.0) 3 (20.0) 0.393*
(*Fisher’s exact test).
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Continuous data were expressed as the median (range) or
mean ± standard deviation (SD) and compared using an
independent two-sample t-test. Survival curves were made
using the Kaplan-Meier method, and groups were com-
pared using the log-rank test. Univariate and multivariate
analyses to identify prognostic predictors were performed
using Cox proportional hazard regression models. Va-
riables with P < 0.10 on univariate analysis were entered
into multivariate analyses.
Statistical analysis was performed using the SPSS statistical
software package, version 18.0 (SPSS Inc., Chicago, IL, USA).
A two-sided P < 0.05 was considered statistically significant.
Results
The baseline patient characteristics and tumor patho-
logical factors are shown in Table 1. Seventy-five percent
of the patients were male, with a mean age of 55 years
(range 22–76 years). Of these patients, 185 (93%) pa-
tients had curative resection, and 14 (7%) patients had
palliative surgery. Clear surgical margins were achieved
in 195 (98%) patients. There were 88 (44.2%) patients
who were at ypT0-2 N0 after neoadjuvant chemoradia-
tion and 38 (19.1%) achieved pathological complete re-
sponse (pCR). One hundred seventeen (58.8%) patients
achieved TRG0-1. For all patients, the baseline median
lymphocyte count was 1.6 × 109/l (range 0.6-3.8), the
median neutrophil count was 3.9 × 109/l (range 1.3-15.7),
and the median NLR was 2.4 (range 1.0-8.9).
Of the 199 rectal cancer patients with baseline blood
sample reports, 19 (9.5%) patients developed local recur-
rence, 49 (24.6%) patients developed distant metastasis
and 43 (21.6%) patients had died by the time of last
follow-up. The median follow-up for survivors was
31 months (range 1–84 months). In the ROC analysis,
the AUC (area under the curve) for NLR was 0.635
(P = 0.007) for OS and 0.569 (P = 0.107) for DFS. The
optimal cut-off value for NLR was 2.8 and 3.6 for OS
and DFS, respectively. Because the NLR could not sta-
tistically discriminate DFS, the cut-off value of 2.8 was
chosen for further analysis. An NLR ≥2.8 was defined as
high NLR, and an NLR < 2.8 was defined as low NLR in
our study.
Table 1 shows the difference in clinicopathological
characteristics between the NLR groups. Overall, 133
(66.8%) patients had a low NLR, and 66 patients (33.2%)
had a high NLR. A high NLR was only significantly asso-
ciated with a higher clinical stage before treatment.
None of the other clinicopathological characteristics
were found to associate with the NLR.
An elevated NLR was a significantly poor prognostic
factor. The 5-year overall survival (OS) in patients with
NLR <2.8 was 0.717 and 0.437 in patients with NLR ≥2.8
(P = 0.002) (Figure 1). The 5-year disease-free survival(DFS) in patients with NLR <2.8 was 0.625, and it was
0.334 in patients with NLR ≥2.8 (P = 0.032) (Figure 2).
The results of the univariate analysis are shown in
Table 2. An elevated NLR before chemoradiation was
significantly associated with decreased OS (HR, 2.526;
95% CI, 1.384-4.610; P = 0.003) and decreased DFS (HR,
1.662; 95% CI, 1.037-2.664; P = 0.035). A multivariate ana-
lysis was performed for the characteristics with P < 0.1 by
univariate analysis (Table 3). This analysis indicated that
NLR (HR, 2.123; 95% CI, 1.140-3.954; P = 0.018), ypTNM
staging (HR, 3.928; 95% CI, 1.651-9.345; P = 0.002) and
adjuvant chemotherapy completion (HR, 3.506; 95% CI,
1.251-9.827; P = 0.017) were associated with OS. NLR
Figure 1 Overall survival stratified by neotrophil-lymphocyte
ratio (NLR).
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0.840-2.214; P = 0.210), and ypTNM staging (HR, 3.477;
95% CI, 1.857-6.509; P < 0.001) was the only factor asso-
ciated with DFS in multivariate analysis.
We also validated the cut-off values from a previous
study in our patient cohort. Carruthers et al. [15] found
that an NLR ≥5 could predict outcome in patients
undergoing neoadjuvant chemoradiation for locally ad-
vanced rectal cancer. In our study, a NLR ≥5 was signifi-
cantly associated with worse OS (HR, 3.286; 95% CI,Figure 2 Disease-free survival stratified by neotrophil-lymphocyte
ratio (NLR).1.362-7.932; P = 0.008) in the univariate analysis and
remained significant in the multivariate analysis (HR,
2.849; 95% CI, 1.097-7.398; P = 0.032). For DFS, NLR ≥5
did not show statistical significance in either the univa-
riate or multivariate analysis. However, there were only
15 (7.5%) patients with NLR ≥5 in our cohort.
The relationship of the tumor response to the mean
NLR and the mean lymphocyte count was analysed. When
we evaluated with ypTNM staging system, the mean NLR
in the ypT0-2 N0 group was 2.68 ± 1.38, and it was 2.77 ±
1.38 in the ypT3-4/N+ group with no statistical signifi-
cance (P = 0.703). The mean lymphocyte count was 1.70 ±
0.57 and 1.70 ± 0.60 for the good and poor response
groups (P = 0.884), respectively. When we evaluated with
TRG system, the mean NLR in the TRG 0–1 group was
2.68 ± 1.42, and it was 2.82 ± 1.33 in the TRG 2–3 group
with no statistical significance (P = 0.873). The mean
lymphocyte count was 1.66 ± 0.54 and 1.76 ± 0.64 for the
good and poor response groups (P = 0.260), respectively.
ROC analysis showed a minimal sensitivity of NLR to pre-
dict ypTNM staging (AUC= 0.526; P = 0.534) or TRG
score (AUC = 0.546; P = 0.268). The chi-square test in
Table 1 also showed no significant association between an
NLR of 2.8 with ypTNM staging or TRG score. Therefore,
NLR and lymphocyte count were unable to predict neoad-
juvant chemoradiation response in these LARC patients.
Discussion
Our study has highlighted the potential ability of NLR to
serve as a prognostic marker for overall survival in lo-
cally advanced rectal cancer (LARC) patients. NLR ≥2.8
is associated with worse survival in these patients under-
going neoadjuvant chemoradiation, but no correlation
was found between NLR and radiation response. Several
translational studies have demonstrated that NLR can
serve as a marker of systemic inflammatory and immune
response and can predict clinically useful outcomes for
multiple cancers, including LARC. Taken together, these
results indicate that the NLR is a simple and robust la-
boratory variable for risk stratification in LARC patients.
The mechanisms of inflammation that promote tumor
progression and immune response suppression remain
under investigation. A high NLR reflects an enhanced
neutrophil response and/or relative lymphopenia. Neu-
trophils are a type of inflammatory cell that could secrete
circulating vascular endothelial growth factor (VEGF),
chemokines and proteases that stimulate angiogenesis,
and these inflammatory cytokines may establish a tumor
microenvironment and promote tumor development and
progression [17,18]. Moreover, an elevated neutrophil
count may activate immunosuppression through the in-
hibition of natural killer cells and activated T cells [19,20].
Furthermore, lymphocytes are thought to be responsible
for the adaptive immune response and participate in
Table 2 Univariate analysis in relation to overall survival and disease-free survival
Patient characteristics Overall survival Disease-free survival
HR 95% CI P-value HR 95% CI P-value
Age, years
<60
≥60 0.954 0.488-1.865 0.891 0.729 0.431-1.234 0.240
Gender
Female
Male 1.029 0.492-2.153 0.939 0.992 0.575-1.714 0.978
Tumor stage before CRT
II
III 7.237 0.992-52.812 0.051 3.468 1.262-9.532 0.016
Tumor location
Low
Middle-high 1.321 0.720-2.426 0.368 1.025 0.635-1.656 0.920
NLR before CRT
Low (<2.8)
High (≥2.8) 2.526 1.384-4.610 0.003 1.662 1.037-2.664 0.035
Platelets count, ×109/l
<300
≥300 0.655 0.258-1.664 0.373 0.813 0.417-1.587 0.544
CEA, ng/ml
<5
≥5 2.014 1.092-3.715 0.025 1.727 1.081-2.761 0.022
RT dose, Gy
45-50
>50 0.801 0.403-1.594 0.527 0.716 0.432-1.185 0.193
Surgical procedure
Curative surgery
Palliative surgery 2.383 0.994-5.713 0.052 2.2 1.048-4.616 0.037
Lymphatic or vascular invasion
No
Yes 2.346 1.085-5.073 0.03 2.274 1.221-4.238 0.010
Neural invasion
No
Yes 1.254 0.557-2.824 0.585 1.382 0.757-2.525 0.293
Circumferential resection margin
Negtive
Positive 1.956 0.470-8.148 0.357 1.454 0.356-5.936 0.602
ypTNM staging
ypT0-2 N0
ypT3-4/N+ 4.223 1.953-9.133 <0.001 4.204 2.337-7.562 <0.001
Shen et al. Radiation Oncology  (2014) 9:295 Page 5 of 8
Table 2 Univariate analysis in relation to overall survival and disease-free survival (Continued)
TRG score
0-1
2-3 1.897 1.031-3.491 0.040 1.714 1.076-2.731 0.023
Adjuvant chemotherapy
Yes
No 2.354 0.982-5.639 0.055 1.294 0.592-2.826 0.518
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Tumor-infiltrating lymphocytes appear to play an anti-
tumorigenic role in colorectal cancer [22]. The proportion
of different subsets of T cells can also influence the clinical
outcome. High densities of CD3+ T cells,
CD8+ cytotoxic T cells and CD45RO+ memory T cells are
typically associated with a longer disease-free survival
(after surgical resection of the primary tumor) and/or
overall survival [23]. Therefore, the NLR may influence
the survival outcome by influencing the tumor micro-
environment and immune system in several types ofTable 3 Multivariate analysis in relation to overall survival an
Patient characteristics Overall survival
HR 95% CI











Palliative surgery 1.289 0.488-3.401











No 3.506 1.251-9.827cancer. More specific studies are needed to combine such
immunohistochemical and bio-molecular analyses.
Although there is a body of evidence suggesting that
an elevated NLR indicates worse survival, the threshold
of NLR ranges between 2 and 5 in different studies of
colorectal cancer [24], and the relationship between
NLR and tumor response to neoadjuvant chemoradio-
therapy remains controversial. Carruthers et al. found
that an elevated NLR was associated with worse survival,
but they found no correlation between NLR and tumor
downstaging [15], which is in agreement with thed disease-free survival
Disease-free survival
P-value HR 95% CI P-value
0.195 2.045 0.724-5.778 0.177
0.018 1.363 0.840-2.214 0.210
0.363 1.427 0.876-2.324 0.153
0.608 1.472 0.680-3.185 0.327
0.409 1.368 0.712-2.629 0.347
0.002 3.477 1.857-6.509 <0.001
0.766 1.027 0.626-1.684 0.916
0.017
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used in their study [15], could discriminate OS in our
cohort as well, but with less sensitivity. Therefore, a
much larger population is needed for identifying the op-
timal cut-off value. Kitayama et al. analyzed 73 locally
advanced rectal cancer patients retrospectively and
showed that the lymphocyte ratio in WBC was signifi-
cantly higher (P = 0.020) and the neutrophil ratio tended
to be lower (P = 0.099) in a pathological complete re-
sponse (pCR) group [14]. Krauthamer et al. reported a
significantly higher probability of pCR to NACRT in pa-
tients with clinical stage III LARC patients who had an
NLR value <5 (OR = 2.54; P = 0.04) by multivariate ana-
lysis, but it should be noted that only 10 patients
achieved pCR [25]. Additional parameters in routine
blood measurements such as platelets may have impli-
cations for the metastasis and prognosis of colorectal
cancer [26]. However, we found that neither NLR nor
lymphocyte counts was associated with tumor response
evaluated with ypTNM staging or TRG score, and no re-
lationship was found between platelet count and tumor
response or survival. A further validation of these dif-
ferences is necessary.
Morever, Kitayama J, et al. found circulating lympho-
cyte count was most markedly decreased in the CRT
period and gradually recovered by the time of surgery,
while the numbers of neutrophils were comparatively
stable [14]. We have observed that the NLR was mainly
influenced by concomittant chemotherapy and granulo-
cyte colony-stimulating factors during the therapeutic
process of chemoradiation. That is, the NLR would like
to decrease after concomittant chemotherapy while in-
crease after treating with granulocyte colony-stimulating
factors. Therefore, the baseline NLR which is not inter-
fered by any therapy is more important as a prognostic
factor for patients.
It should be noted that although the NLR is easy to
measure, its utility as a marker of systemic inflammation
may be affected by many conditions, including coronary
disease [27], metabolic syndrome [28], inflammatory dis-
eases and any medication related to inflammatory condi-
tions in the patients. These limitations must be
considered because this is a retrospective study, and no
specific data were available about co-morbidities and the
cause of death. These variables will influence the specifi-
city of NLR as a prognostic factor in our rectal cancer pa-
tient cohort. Another limitation is that 86.9% of the
patients in our cohort with stage III have a worse 5-year
OS (62%) compared with well-organised randomized clin-
ical trial patients (76%) [29]. This result is likely because
our cohort is a routine locally advanced rectal cancer
population without strict inclusion criteria for neoadju-
vant chemoradiation. Although there was no significant
difference in the DFS between the NLR groups accordingto the multivariate analysis, the difference may be signifi-
cant with a longer follow-up time and a larger patient
population.
Even considering these limitations, our data indicate
that an elevated pre-treatment NLR may serve as a prog-
nostic marker for risk stratification in locally advanced
rectal cancer patients who received neoadjuvant che-
moradiation. In addition, tumor response, which is the
tumor stage after treatment, and the ability to receive
adjuvant chemotherapy remain the most significant
prognostic factors for overall survival in the multivariate
analysis. In this study, the NLR did not represent a alter-
nate factor for either of them. Although systemic adju-
vant chemotherapy is an independent prognostic factor
for OS in our study, the benefit of adjuvant chemo-
therapy remains controversial. The EORTC 22921 study
showed that the addition of adjuvant chemotherapy
benefited only the group of patients who had a reduction
in tumor stage to ypT0-2, while there was no benefit in
the group who had no tumor reduction (ypT3-4) [30].
The ongoing NCT01941979 study is the first phase III
randomized trial comparing adjuvant chemotherapy and
observation for rectal adenocarcinoma patients with
ypT3-4, N0-1 after neoadjuvant chemoradiotherapy. The
investigator believes that this subgroup of patients will
benefit from adjuvant therapy [31]. Therefore, it may
make sense for patients with elevated NLR to receive in-
tensive preoperative treatment because the postoperative
chemotherapy remains controversial.Conclusion
In conclusion, our study demonstrated that the pre-
treatment NLR may be an independent, significant pre-
dictor of long-term mortality in locally advanced rectal
cancer patients undergoing neoadjuvant chemoradiation.
Large-scale prospective studies and a validation study are
warranted to confirm the optimal NLR cut-off value and
its prognostic significance.
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